- Online Form
Abstract Submission Deadline: 15/10/2020
Elisa BorghiUniversity of Milan, Italy
Elisa Borghi is an Assistant Professor in Microbiology at the University of Milan. She received her PhD in Molecular Medicine from the University of Milan, during which she was a research assistant for a few months at the Centre for Neurovirology and Cancer Biology of the Temple University of Philadelphia.
Her scientific activity has involved several fields of interest. She has done extensive research on the involvement of neurotropic viruses in aetiology of neurodegenerative disorders, especially studying Polymaviruses infection in HIV positive patients. She has also collaborated with Prof. Morace in the study of molecular aspects of bacterial and fungal infections, focusing on rapid diagnosis and molecula typing of clinical isolates. Her most recent work has concentrated on microbial biofilm, especially in terms of antimicrobial drug resistance.
Prof. Borghi interest lies in the study of molecular mechanisms involved in pathogensis and antifungal resistance of bacterial, and fungal strains organised in mono and poly microbial biofilm.
Juliana Campos JunqueiraUniversidade Estadual Paulista, Brazil
Juliana Junqueira is Associate Professor of Oral Microbiology and Immunology in the Institute of Science and Technology at São Paulo State University/UNESP and Researcher on Productivity at the National Counsel of Technological and Scientific Development/CNPq (Brazil). Dr. Junqueira studies host-pathogen interactions in animal models to identify new antimicrobial agents for the treatment of oral infectious diseases. These studies resulted in more than 100 scientific articles and 12 book chapters in the medical and dental areas.
Olivia ChampionBioSystems Technology Ltd
Olivia has over 10 years’ experience in the development and commercialisation of in vivo screening technologies using Galleria mellonella. She has capitalised on her strong international network to rapidly grow BioSystems Technology into the leading global supplier of G. mellonella for research, increasingly forging strong partnerships with EU and UK CROs. Previously Olivia carried out a Masters degree in Clinical Microbiology at the Queen Mary and Westfield University in London whilst working as a Clinical Scientist for Public Health England. She completed a PhD in molecular microbiology at the London School of Hygiene and Tropical Medicine and she carried out post-doctoral research at the University of British Columbia in Vancouver, Canada and the University of Exeter.
Julia FrickUniversitatsklinikum Tubingen, Tubingen, Germany
Prof. Julia Frick specialised in medical microbiology at the Institute of Medical Microbiology and Hygiene at the University Hospital of Tübingen, where she was appointed a Professor for Mucosal Immunology and Microbiome in 2012. She is currently employed as a senior physician, Deputy Medical Director and Group Leader at the Institute of Medical Microbiology and Hygiene, University of Tübingen. Since 2016 she is the Vice-Chairman of the DGMIM.
In 2008 she was awarded with the career award „Förderpreis“ of the German Society for Hygiene and Microbiology and in 2015 with the Oskar Medizin Preis.
Her scientific focus lies in the understanding for the role of host-microbiota interactions in the development or prevention of chronic systemic or intestinal inflammatory disorders.
Paul LangfordImperial University, UK
After completing his PhD in pharmaceutical microbiology at the University of Aston, Prof. Paul Langford concentrated on respiratory and invasive diseases, and meningitis-causing pathogens of man, e.g. Neisseria meningitidis, Haemophilus influenzae and Mycobacterium tuberculosis, and animals e.g. Actinobacillus pleuropneumoniae (APP), Haemophilus parasuis, Pasteurella multocida.
Currently a Professor of Paediatric Infectious Diseases, Section of Paediatrics, Imperial College London, he is widely recognised for his work on the use of reverse vaccinology 2.0 (including antibody cloning from patients) approaches for vaccine discovery to prevent meningococcal and pneumococcal disease. The aims of his research are to improve vaccines, diagnostics, therapeutics and to achieve a greater understanding of the basis of bacterial pathogenicity. Prof. Langford also has interests in the discovery of host biomarkers to diagnose typhoid and tuberculosis.
In collaboration with the National University of Singapore and the Institute of Bioengineering and Nanotechnology, Singapore, and the Imperial College London, Prof. Langford designed antimicrobial peptides, which are being tested for their efficacy in vitro and in vivo to inhibit M. tuberculosis. He is also a local Biological Safety Officer and GMSC chair.
Eleftherios MylonakisMedical School of Brown University, Rhode Island, US
Dr. Eleftherios Mylonakis, Charles C.J. Carpenter Professor of Infectious Disease at Brown University, is also the Chief of Infectious Diseases at Rhode Island Hospital and the Miriam Hospital. Dr. Mylonakis studies host and microbial factors of infection and the discovery of antimicrobial agents. His research encompasses both translational and laboratory studies and the use of mammalian and invertebrate model hosts systems to identify novel antimicrobial compounds and the elucidation of evolutionarily conserved aspects of microbial virulence and the host response. Especially, the development of invertebrate models including the insect Galleria mellonella has been a major focus of his laboratory and this work has developed a number of models to study host-pathogen interactions. These investigations have identified novel virulence factors, cross kingdom pathogen-pathogen interactions, novel antimicrobial agents, and traits involved in host virulence and immune responses during infection. He has 8 patents, edited five books and over 325 articles in the peer-reviewed literature.
Emerenziana OttavianoUniversity of Milan, Italy
Rick TitballUniversity of Exeter, UK
Richard Titball is a Professor of Molecular Microbiology at the University of Exeter and was previously a Senior Fellow at the Defense Science and Technology Laboratory. He is a bacteriologist with a strong interest in the molecular basis of bacterial pathogenicity, which he uses to develop improved vaccines and antibacterial therapies for disease in humans and animals.
He is appointed as the academic leader of the Microbes and Disease research group and Head of Biosciences at the university. He is also a co-founder of Biosystems Technology, a spin out company of the University of Exeter, which specialises in alternative infection models.
He has published more than 300 peer-reviewed papers, filed 20 patents and currently serves as an Editor of Vaccine and an Editorial Board Member of NPJ Vaccines.